A new PET imaging approach using carbonic anhydrase IX (CAIX) detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), outperforming ¹⁸F-FDG PET/CT. The approach improved patient-level diagnostic accuracy in ccRCC, leading to changes in clinical management or disease stage in 30.9% of patients.
Researchers developed a next-generation PET/CT scanner that produces diagnostic-quality images in as little as one minute, surpassing the performance of conventional scanners. The study showed that even 90% shorter scans maintained high image quality, making it a game-changer for cancer diagnosis and treatment.
Nuclear medicine is experiencing rapid growth with over 50 million procedures performed worldwide each year. EANM'26 will present the latest advances in nuclear medicine, molecular imaging, and radiopharmaceuticals, including theranostics and next-generation imaging technology.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.